A Phase 2 interventional study of PF-3512676 + Erlotinib and Erlotinib in Carcinoma, Non-Small-Cell Lung, sponsored by Pfizer. Completed at 35 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-23.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
To assess the efficacy and safety of PF-3512676 administered in combination with erlotinib in patients with advanced EGFR-positive non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
6,641 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,665 are open to participants now.
This study's enrollment of 43 is below the median of 62 across 5,327 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Pfizer is the lead sponsor of 3,323 studies on the registry; 145 are open to participants now.
Of its 597 completed or terminated interventional studies of FDA-regulated products, 391 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Standard of Care chemotherapy plus experimental intervention (PF-3512676)
Drug: PF-3512676 + Erlotinib
Standard of Care chemotherapy
Drug: Erlotinib
Drug pages: ProMune · Erlotinib
PF-3512676 0.2 mg/kg subcutaneously on days 1, 8 and 15 of each 21 day cycle until disease progression or unacceptable toxicity. Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
Also known as: Tarceva
Progression-Free Survival
Time frame: 50Events
Overall Safety Profile
Time frame: 28 days post treatment
Time to Tumor Progression
Time frame: End of treatment
Overall Objective Response Rate
Time frame: Time of disease progression
Duration of Response
Time frame: Time of disease progression
Overall Survival
Time frame: Time of death
The record gives a start of Aug 2006, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: ProMune · Erlotinib
Carcinoma, Non-Small-Cell Lung →